Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 14/20 | 0.67 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471280 | 1.00 | AVPR1A (0.67) | AVPR1AHTR6CNR1CCR5CNR2 | |
| SCHEMBL4360957 | 0.92 | AVPR1A (0.58) | AVPR1AHTR6CNR1CCR5OXTR | |
| SCHEMBL4360960 | 0.92 | AVPR1A (0.58) | AVPR1AHTR6CNR1CCR5OXTR | |
| SCHEMBL4362779 | 0.88 | AVPR1A (0.68) | AVPR1ACNR1CCR5OXTRALDH1A1 | |
| SCHEMBL4362783 | 0.88 | AVPR1A (0.68) | AVPR1ACNR1CCR5OXTRALDH1A1 | |
| SCHEMBL4359931 | 0.85 | AVPR1A (0.60) | AVPR1ACNR1OXTRALDH1A1 | |
| SCHEMBL4359929 | 0.85 | AVPR1A (0.60) | AVPR1ACNR1OXTRALDH1A1 | |
| SCHEMBL8248324 | 0.84 | AVPR1A (0.56) | AVPR1ACNR1CCR5OXTRALDH1A1 | |
| SCHEMBL4356097 | 0.83 | AVPR1A (0.69) | AVPR1AHTR6CNR1CNR2OXTR | |
| SCHEMBL4356093 | 0.83 | AVPR1A (0.69) | AVPR1AHTR6CNR1CNR2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | AVPR1A, AVPR2, OXTR | AVPR1A 1/4885HTR6 81/4885CNR1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.